Evidence map›Paper›PMID 39102242›Full record

ArticleTranslational vision science & technology2024

Topographic Clinical Insights From Deep Learning-Based Geographic Atrophy Progression Prediction.

Julia Cluceru, Neha Anegondi, Simon S Gao, Aaron Y Lee, Eleonora M Lad, Usha Chakravarthy, Qi Yang, Verena Steffen, Michel Friesenhahn, Christina Rabe and 1 more

3 registry-linked trialsAbstract read
In one paragraph

Article in Translational vision science & technology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02247479 phase3terminatednot on this map

A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration

TypeinterventionalSponsorHoffmann-La RocheRan2014 to 2018Enrolled906ConditionsGeographic AtrophyArmsLampalizumab, Sham
NCT02247531 phase3terminatednot on this map

A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration

TypeinterventionalSponsorHoffmann-La RocheRan2014 to 2018Enrolled975ConditionsGeographic AtrophyArmsLampalizumab, Sham Comparator
NCT02479386 terminatednot on this map

A Multicenter, Prospective Epidemiologic Study of The Progression of Geographic Atrophy Secondary to Age-Related Macular Degeneration

TypeobservationalSponsorHoffmann-La RocheRan2015 to 2018Enrolled296ConditionsGeographic AtrophyArmsNo intervention
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Julia CluceruGenentech, Inc., South San Francisco, CA, USA.
Neha AnegondiGenentech, Inc., South San Francisco, CA, USA.
Simon S GaoGenentech, Inc., South San Francisco, CA, USA.
Aaron Y LeeRoger and Angie Karalis Johnson Retina Center, University of Washington, Seattle, WA, USA.
Eleonora M LadDepartment of Ophthalmology, Duke University Medical Center, Durham, NC, USA.
Usha ChakravarthyRoyal Victoria Hospital (The Belfast Trust), Queens University of Belfast, Belfast, UK.
Qi YangGenentech, Inc., South San Francisco, CA, USA.
Verena SteffenGenentech, Inc., South San Francisco, CA, USA.
Michel FriesenhahnGenentech, Inc., South San Francisco, CA, USA.
Christina RabeGenentech, Inc., South San Francisco, CA, USA.
Daniela FerraraGenentech, Inc., South San Francisco, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: To explore the contributions of fundus autofluorescence (FAF) topographic imaging features to the performance of convolutional neural network-based deep learning (DL) algorithms in predicting geographic atrophy (GA) growth rate. Methods: Retrospective study with data from study eyes from three clinical trials (NCT02247479, NCT02247531, NCT02479386) in GA. The algorithm was initially trained with full FAF images, and its performance was considered benchmark. Ablation experiments investigated the contribution of imaging features to the performance of the algorithms. Three FAF image regions were defined relative to GA: Lesion, Rim, and Background. For No Lesion, No Rim, and No Background datasets, a single region of interest was removed at a time. For Lesion, Rim, and Background Shuffled datasets, individual region pixels were randomly shuffled. For Lesion, Rim, and Background Mask datasets, masks of the regions were used. A Convex Hull dataset was generated to evaluate the importance of lesion size. Squared Pearson correlation (r2) was used to compare the predictive performance of ablated datasets relative to the benchmark. Results: The Rim region influenced r2 more than the other two regions in all experiments, indicating the most relevant contribution of this region to the performance of the algorithms. In addition, similar performance was observed for all regions when pixels were shuffled or only a mask was used, indicating intensity information was not independently informative without textural context. Conclusions: These ablation experiments enabled topographic clinical insights on FAF images from a DL-based GA progression prediction algorithm. Translational Relevance: Results from this study may lead to new insights on GA progression prediction.

Indexed as

Deep LearningDisease ProgressionGeographic AtrophyAgedAlgorithmsClinical Trials as TopicFemaleFluorescein AngiographyHumansMaleMiddle AgedNeural Networks, ComputerOptical ImagingRetrospective Studies

Identifiers

PMID39102242
PMCPMC11309039

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.